LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
=== Subsequent developments === It was also realized that the beta decay of 239Np must produce an isotope of element 94 (now called plutonium), but the quantities involved in McMillan and Abelson's original experiment were too small to isolate and identify plutonium along with neptunium. The discovery of plutonium had to wait until the end of 1940, when Glenn T. Seaborg and his team identified the isotope plutonium-238. In 1942, Hahn and Fritz Strassmann, and independently Kurt Starke, reported the confirmation of element 93 in Berlin. Hahn's group did not pursue element 94, likely because they were discouraged by McMillan and Abelson's lack of success in isolating it. Since they had access to the stronger cyclotron at Paris at this point, Hahn's group would likely have been able to detect element 94 had they tried, albeit in tiny quantities (a few becquerels). Neptunium's unique radioactive characteristics allowed it to be traced as it moved through various compounds in chemical reactions, at first this was the only method available to prove that its chemistry was different from other elements. As the first isotope of neptunium to be discovered has such a short half-life, McMillan and Abelson were unable to prepare a sample that was large enough to perform chemical analysis of the new element using the technology that was then available. However, after the discovery of the long-lived 237Np isotope in 1942 by Glenn Seaborg and Arthur Wahl, forming weighable amounts of neptunium became a realistic endeavor.
1978 Genentech produces biosynthetic human insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly 1981 Novo Nordisk chemically and enzymatically converts porcine to human insulin 1982 Genentech synthetic human insulin (above) approved 1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin 1996 Lilly Humalog "lispro" insulin analogue approved. 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and the EU. 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US. 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US. 2008 Abbott laboratories " FreeStyle Navigator CGM" gets approved. 2013 The US Food and Drug Administration (FDA) requested more cardiac safety tests for Insulin degludec. 2015 Insulin degludec was approved by the FDA in September 2015.
We went to South Ossetia on the night of August 7. Around noon of 7 August, the column was near Tskhinvali on the bypass road." In August 2009, Russian military reporter Alex Kots quoted Andrey Kazachenko, commander of the 693rd Regiment, as saying that the General Staff of Russia issued an order to begin movement towards Tskhinvali at 8:20 PM on August 7. In August 2009, Major of the Medical Service Dmitry Zubok told radio station moskva.fm that several surgeons, including him, were sent to South Ossetia on 14 July 2008 in anticipation of conflict and that the armed hostilities began on 6 August 2008. In September 2009, an independent documentary "Russian Lessons" was premiered in Saint Petersburg. Russian film makers Andrei Nekrasov and Olga Konskaya disputed the narrative of the Russian government (supported by the most Western media at the time) and examined wartime propaganda. The film also includes a testimony by a father of Russian soldier that his son was sent to the war on 5 August 2008.
==== HIV/AIDS ==== In 2013, scientists have been investigating an alternative approach to treating HIV-1/AIDS, based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1-resistant) hematopoietic stem and progenitor cells (GM-HSPC).
Sources: en.wikipedia.org
His wife also says that Edwards is receiving in-patient hospital care after an episode of depression following the publication of the allegations. Following an investigation into the allegations, the Metropolitan Police releases a statement to say detectives have determined no criminal offence has been committed. The Bank of England says that rising interest rates mean that mortgages for at least one million borrowers will rise by an average of £500 a month by the end of 2023. The 2.6 GW Hornsea Project 4 is approved by the government, becoming the second-largest UK wind farm to receive planning consent, following Hornsea Project Three. 13 July The longest doctor's strike in NHS history begins, as junior doctors begin a five-day walkout over pay. The government offers more than a million public sector workers in England and Wales a pay rise worth an average of 6%. The offer sees police and prison officers in England and Wales offered 7%, with teachers in England offered 6.5%, and junior doctors in England offered 6%. A report published by the Intelligence and Security Committee of Parliament says the UK failed to develop an effective strategy for dealing with threats to its national security by China, which has allowed Chinese intelligence to aggressively target the UK. 14 July Data published by the Office for National Statistics indicates one in 20 people surveyed reported running out of food, and being unable to afford to buy more because of rising food prices.
1898: Danish physicist Kirstine Meyer was awarded the gold medal of the Royal Danish Academy of Sciences and Letters. 1898: Italian malacologist Marianna Paulucci donated her collection of specimens to the Royal Museum of Natural History in Florence, Italy (Museo di Storia Naturale di Firenze). Paulucci was the first scientist to compile and publish a species list of Italian malacofauna. 1899: American physicists Marcia Keith and Isabelle Stone became charter members of the American Physical Society. 1899: Irish physicist Edith Anne Stoney was appointed a physics lecturer at the London School of Medicine for Women, becoming the first female medical physicist. She later became a pioneering figure in the use of X-ray machines on the front lines of World War I.
In Korean cuisine, glass noodles are usually made from sweet potato starch and are called dangmyeon (Korean: 당면; Hanja: 唐麵; literally "Tang noodles"; also spelled dang myun, dangmyun, tang myun, or tangmyun). They are commonly stir-fried in sesame oil with beef and vegetables, and flavoured with soy and sugar, in a popular dish called japchae (잡채). They are usually thick, and are a brownish-gray color when in their uncooked form.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.